Kura Oncology Announces FDA Clearance For IND Application For KO-2806

Kura Oncology, Inc. (KURA) announced the clearance by the FDA of the Investigational New Drug application for KO-2806 for the treatment of advanced solid tumors. The company plans to evaluate safety, tolerability and preliminary antitumor activity of KO-2806 in a Phase 1 first-in-human study as a monotherapy and in combination with other targeted therapies.

KO-2806 is a potent next-generation inhibitor of farnesyl transferase designed to improve upon potency, pharmacokinetic and physicochemical properties of earlier FTI drug candidates.

Kura Oncology expects to initiate the Phase 1 study in the third quarter of 2023.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT